Summary of Study ST002047

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001294. The data can be accessed directly via it's Project DOI: 10.21228/M8FQ39 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Study ID	ST002047
Study Title	Lyso-lipid induced oligodendrocytes maturation underlie restoration of optic nerve function
Study Summary	Protein hyper-deimination and deficiency of lyso-phospholipids (LPC 18:1) has been associated with the pathology of demyelinating disease in both humans and mice. We uncovered interesting biology of LPC 18:1, in which LPC 18:1 induced optic nerve function restoration through oligodendrocyte maturation and remyelination in mouse model systems. Our in vitro studies show LPC 18:1 protection against neuron-ectopic hyper-deimination and stimulation of oligodendrocyte maturation, while in vivo investigations recorded optic nerve function improvement following optic nerve injections of LPC 18:1, in contrast to LPC 18:0. Thus just a change in a single bond renders a dramatic alternation in biological function. The incorporation of isobaric C13-histidine in newly synthesized myelin proteins and quantitative proteome shifts are consistent with remyelination underlying restoration in optic nerve function. These results suggest that exogenous LPC 18:1 may provide a therapeutic avenue for stemming vision loss in demyelinating diseases.
Institute	University of Miami
Last Name	Bhattacharya
First Name	Sanjoy K.
Address	1638 NW 10th Avenue, Room 706-A, Miami, FL 33136
Email	sbhattacharya@med.miami.edu
Phone	3054824103
Submit Date	2021-12-16
Raw Data Available	Yes
Raw Data File Type(s)	raw(Thermo)
Analysis Type Detail	LC-MS
Release Date	2022-01-21
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR002141
Treatment Summary:	siRNA and overexpression. Cell transfection was carried using the INTERFERin transfection kit following manufacture’s recommendations (Polyplus Transfection, 89129-930). siRNA for LPCAT1, PLA2G4C, and LIPC were purchased from Ambion (Ambion, s102346, s107315, s67780 respectively), LPGAT1 and LIPC overexpression constructs were purchased from Genecopoeia (Genecopoeia, EX-mm15104-M61, EX-mm03119-M61). In brief, cells were transfected with 2 nM of siRNA or DNA in serum free cell culture media. INTERFERin reagent was added to the mix incubated at room temperature for 10 minutes and added to newly changed cell culture media for each well. Cells were incubated for 48 to 96 hours before harvesting.

Treatment ID:

TR002141

Treatment Summary:

siRNA and overexpression. Cell transfection was carried using the INTERFERin transfection kit following manufacture’s recommendations (Polyplus Transfection, 89129-930). siRNA for LPCAT1, PLA2G4C, and LIPC were purchased from Ambion (Ambion, s102346, s107315, s67780 respectively), LPGAT1 and LIPC overexpression constructs were purchased from Genecopoeia (Genecopoeia, EX-mm15104-M61, EX-mm03119-M61). In brief, cells were transfected with 2 nM of siRNA or DNA in serum free cell culture media. INTERFERin reagent was added to the mix incubated at room temperature for 10 minutes and added to newly changed cell culture media for each well. Cells were incubated for 48 to 96 hours before harvesting.